-
Mashup Score: 0Renal Cell Carcinoma Roundtables - 25 day(s) ago
Read the full article here
Tweet
-
Mashup Score: 0
Read the full article here
Tweet-
Daniel J. George, MD, FASCO, of Duke University, shares his expert opinion on the 8-year CheckMate 214 survival and durable response data, as well as whether this data strengthens the argument for IO/IO in any given risk group.
-
-
Mashup Score: 0Frontline RCC Treatment Selection: IO/IO Versus IO/TKI - 3 month(s) ago
Read the full article here
Tweet-
Favorable-risk patients often have low burden disease and can afford further treatment if necessary. It is encouraging to see this evolving data.
-
-
Mashup Score: 0The Role of SBRT and Metastasis-Directed Therapy for RCC Treatment, Variant Histology Considerations - 3 month(s) ago
Read the full article here
Tweet-
Data from ASCO GU 2024 altered the treatment paradigm for RCC. In this panel, we discussed the role of SBRT, metastasis-directed therapy in RCC, and variant histology considerations.
-
-
Mashup Score: 0Panel Discussion on OS Data From KEYNOTE-564 Study and Post-Relapse Treatment Selection - 3 month(s) ago
Read the full article here
Tweet-
In this panel, we discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for practice.
-
-
Mashup Score: 0Advanced Renal Cell Carcinoma - 25 day(s) ago
Read the full article here
Tweet-
Latest news from GU Oncology Now on advanced renal cell carcinoma.
-
-
Mashup Score: 02024 ASCO GU Symposium: Focus on Renal Cell Carcinoma - 25 day(s) ago
Read the full article here
Tweet-
Stay up-to-date with the latest research and clinical updates on renal cell carcinoma from the 2024 ASCO GU Symposium.
-
This page features a medley of roundtables led by field experts in RCC. The first collection, moderated by Rana McKay, MD, delve into a plethora of topics in kidney cancer.